References
Predictors of thromboembolism in atrial fibrillation: II. Echocardiographic features ofpatients at risk. The Stroke Prevention in Atrial Fibrillation Investigators. Ann Int Med 1992;116:6–12.
Predictors of thromboembolism in atrial fibrillation: I. Clinical features of patients at risk. The StrokePrevention in Atrial Fibrillation Investigators. Ann Int Med 1992;116:1–5.
Patients withnon-valvular atrial fibrillation at low risk of stroke during treatment with aspirin: Stroke Prevention in Atrial Fibrillation III Study. The SPAF III Writing Committee for the Stroke Prevention in Atrial Fibrillation Investigators. JAMA 1998;279:1273–1277.
Cowburn P, Cleland JG. SPAF-III results. Eur Heart J1996;17:1129.
Adjusted-dose warfarin versus low-intensity, fixeddose warfarin plus aspirin forhigh-risk patients with atrial fibrillation: Stroke prevention in atrial fibrillation III randomized clinical trial. Lancet 1996;348:633–638.
Kistler JP, et al. Effect of low-intensity warfarin anticoagulation on level ofactivity of the hemostatic system in patients with atrial fibrillation. BAATAF Investigators. Stroke 1993;24:1360–1365.
Singer DE, et al. The effect of aspirin on the risk of stroke in patients withnonrheumatic atrial fibrillation: The BAATAF Study. Am Heart J 1992;124:1567–1573.
Cohen IS, Ezekowitz MD. Prevention of thromboembolism in patients with atrial fibrillation. CardiolClin 1996;14:537–542.
Klein AL, et al. Cardioversion guided by transesophagealechocardiography: The ACUTE Pilot Study. A randomized, controlled trial. Assessment of Cardioversion using transesophageal echocardiography. Ann Int Med 1997;126:200–209.
Klein AL, Grimm RA, Murray RD, Apperson-Hansen C, Asinger RW, Black LW, Davidoff R, Erbel R, Halperin JL, Orsinelli DA, Porter TR, Stoddard MF. Use of Transesophageal Echocardiography to Guide Cardioversion in Patients with Atrial Fibrillation. N Engl J Med 2001;344:1411–1420.
Collins LJ, et al.Cardioversion of nonrheumatic atrial fibrillation. Reduced thromboembolic complications with 4 weeks of precardioversion anticoagulation are related to atrial thrombus resolution. Circulation 1995;92:160–163.
Corrado G, et al. A trial thrombi resolution after prolonged anticoagulation in patients with atrialfibrillation. Chest 1999;115:140–143.
Jaber WA, et al. Efficacy of anticoagulation inresolving left atrial and left atrial appendage thrombi: A transesophageal echocardiographic study. Am Heart J 2000;140:150–156.
Laupacis A, et al. Antithrombotic therapy in atrial fibrillation. Chest1998;114(Suppl 5):579S–589S.
Albers GW. Choice of antithrombotic therapy for strokeprevention in atrial fibrillation: Warfarin, aspirin, or both? Arch Intern Med 1998;158:1487–1491.
Klein AL, Murray RD, Grimm RA. Role of Transesophageal Echocardiography-guided Cardioversion ofPatients with Atrial Fibrillation. J Am Coll Cardiol 2001;37;691–704.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Jaber, W.A., Klein, A.L. Prevention of Thromboembolism in the Unstable or Complex Patient with Atrial Fibrillation. Card Electrophysiol Rev 5, 187–188 (2001). https://doi.org/10.1023/A:1011484817371
Issue Date:
DOI: https://doi.org/10.1023/A:1011484817371